Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 26, 2015, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $197.27 to $183,764,684.16.

Highlighted Stocks Traded by Insiders:

Merrimack Pharmaceuticals (MACK) - FREE Research Report

Porter Michael E, who is Director at Merrimack Pharmaceuticals, bought 5,000 shares at $11.70 on March 26, 2015. Following this transaction, the Director owned 653,164 shares meaning that the stake was boosted by 0.77% with the 5,000-share transaction.

The shares most recently traded at $11.63, down $0.07, or 0.6% since the insider transaction. Historical insider transactions for Merrimack Pharmaceuticals go as follows:

  • 4-Week # shares bought: 16,190
  • 12-Week # shares bought: 16,190
  • 24-Week # shares bought: 101,099

The average volume for Merrimack Pharmaceuticals has been 1.5 million shares per day over the past 30 days. Merrimack Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector and drugs industry. Shares are down 0.44% year-to-date as of the close of trading on Thursday.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Currently, there are 5 analysts who rate Merrimack Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MACK - FREE

TheStreet Quant Ratings rates Merrimack Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow. Get the full Merrimack Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Nuance Communications (NUAN) - FREE Research Report

Robbins William T, who is Executive Vice President World at Nuance Communications, sold 2,500 shares at $14.15 on March 26, 2015. Following this transaction, the Executive Vice President World owned 191,228 shares meaning that the stake was reduced by 1.29% with the 2,500-share transaction.

The shares most recently traded at $13.96, down $0.19, or 1.37% since the insider transaction. Historical insider transactions for Nuance Communications go as follows:

  • 4-Week # shares bought: 11,657
  • 4-Week # shares sold: 4,000
  • 12-Week # shares bought: 11,657
  • 12-Week # shares sold: 303,923
  • 24-Week # shares bought: 11,657
  • 24-Week # shares sold: 320,923

The average volume for Nuance Communications has been 2.2 million shares per day over the past 30 days. Nuance Communications has a market cap of $4.6 billion and is part of the technology sector and computer software & services industry. Shares are down 1.89% year-to-date as of the close of trading on Thursday.

Nuance Communications, Inc. provides voice and language solutions for businesses and consumers worldwide. Currently, there are 2 analysts who rate Nuance Communications a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUAN - FREE

TheStreet Quant Ratings rates Nuance Communications as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we find that the stock has had a generally disappointing performance in the past year. Get the full Nuance Communications Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Newfield Exploration (NFX) - FREE Research Report

Shultz Charles E, who is Director at Newfield Exploration, sold 1,250 shares at $35.00 on March 26, 2015. Following this transaction, the Director owned 29,102 shares meaning that the stake was reduced by 4.12% with the 1,250-share transaction.

The shares most recently traded at $34.20, down $0.80, or 2.34% since the insider transaction. Historical insider transactions for Newfield Exploration go as follows:

  • 4-Week # shares sold: 1,250
  • 12-Week # shares sold: 7,500
  • 24-Week # shares sold: 15,500

The average volume for Newfield Exploration has been 4.1 million shares per day over the past 30 days. Newfield Exploration has a market cap of $4.6 billion and is part of the basic materials sector and energy industry. Shares are up 26.25% year-to-date as of the close of trading on Thursday.

Newfield Exploration Company, an independent energy company, engages in the exploration, development, and production of crude oil, natural gas, and natural gas liquids. The company has a P/E ratio of 7.2. Currently, there are 13 analysts who rate Newfield Exploration a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NFX - FREE

TheStreet Quant Ratings rates Newfield Exploration as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income and attractive valuation levels. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Newfield Exploration Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Data for this article provided by Zacks Investment Research

null